⚠️
Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Elevated cost per beneficiary
Risk indicators are statistical patterns, not allegations. Learn more
11,321
Total Claims
$4.2M
Drug Cost
638
Beneficiaries
$6,625
Cost/Patient
Risk Score Breakdown 3/100
Low (0)Moderate (15)Elevated (30)High (50+)
Cost per patient outlier+3
Score components are additive. Read full methodology
Peer Comparison vs. 6,382 Endocrinology providers
+68%
Cost per patient vs peers
$6,625 vs $3,933 avg
-9%
Brand preference vs peers
46.8% vs 51.2% avg
Brand vs Generic
53% generic
Brand: 4,862 claims · $4.0M
Generic: 5,525 claims · $139K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Dulaglutide | 999 | $1.1M |
| Semaglutide | 295 | $318K |
| Dapagliflozin Propanediol | 311 | $229K |
| Empagliflozin | 269 | $220K |
| Denosumab | 109 | $185K |
| Insulin Aspart | 200 | $150K |
| Finerenone | 174 | $133K |
| Sitagliptin Phosphate | 174 | $131K |
| Tirzepatide | 97 | $115K |
| Linagliptin | 164 | $95K |
| Insulin Glargine,hum.Rec.Anlog | 156 | $89K |
| Insulin Lispro | 120 | $87K |
| Insulin Degludec | 89 | $77K |
| Romosozumab-Aqqg | 27 | $67K |
| Abaloparatide | 25 | $64K |
Prescribing Profile
Patient Profile
72
Avg Age
65%
Female
1.70
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About